BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

...18.4%; 6 Dimensions Capital and HH RSV-MIM Holdings Ltd. each have a 9.2% stake; and TLS...
BioCentury | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

...subunit β (ATP5F1B) Patient sample and fruit fly studies suggest inhibiting ATP5F1B could help treat FUS...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Neurology

...dementia. In postmortem brain samples from patients with FUS-associated frontotemporal lobe dementia, immunoelectron microscopy showed FUS...
...in animal models of FUS proteinopathy. TARGET/MARKER/PATHWAY: ATP synthase F1 subunit β (ATP5F1B); fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS...
...Quang Chinese Academy of Sciences Northwestern University Feinberg School of Medicine ATP synthase F1 subunit beta (ATP5F1B) Fusion (involved in t(12;16) in malignant liposarcoma) (FUS) (TLS) Frontotemporal...
BioCentury | Aug 10, 2018
Company News

Genprex to evaluate effect of Oncoprex on checkpoint inhibition with MD Anderson

Genprex Inc. (NASDAQ:GNPX) will sponsor a preclinical program at the University of Texas MD Anderson Cancer Center (Houston, Texas) aimed at evaluating the effect of Genprex's Oncoprex on checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 therapies....
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...studies suggest promoting the expression of TNPO1 could help treat ALS caused by fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS...
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology; musculoskeletal

...fruit fly studies suggest promoting the expression of TNPO1 could help treat ALS caused by FUS...
...expression in models of ALS and multisystem proteinopathy. TARGET/MARKER/PATHWAY: Transportin 1 (TNPO1; KPNB2); fusion (involved in t(12;16) in malignant liposarcoma) (FUS; TLS...
...Children’s Research Hospital, Memphis, Tenn. email: jpaul.taylor@stjude.org Claire Quang St. Jude Children's Research Hospital University of Pennsylvania Fusion (involved in t(12;16) in malignant liposarcoma) (FUS) (TLS) Heterogeneous...
BioCentury | Apr 7, 2017
Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
BioCentury | Jan 27, 2017
Clinical News

Oncoprex: Interim Ph II data

Interim data from 9 evaluable patients with stage IV NSCLC who failed ≥2 treatment regimens in an open-label, U.S. Phase II trial showed that IV Oncoprex every 3 weeks plus Tarceva erlotinib led to a...
BioCentury | Mar 12, 2015
Targets & Mechanisms

TBK1 and beyond

...The aggregates can be caused by mutations in several genes, notably SOD1 , TARDBP or FUS...
...Yale School of Medicine, New Haven, Conn. Targets and Compounds FUS ( TLS ) - Fusion (involved in t(12;16) in malignant liposarcoma)...
...gene transcription via interferon (IFN) activation, and IFN-regulated gene expression contributes to neurodegeneration. FUS ( TLS...
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Neurology

...seven skipping could help prevent the accumulation of mutant FUS protein in ALS motor neurons. FUS...
...and accumulates in the cytoplasm to become neurotoxic. In vitro and in cultured cells, wild-type FUS...
...mutant FUS variants with defective autoregulation, antisense oligonucleotides targeting a flanking splice site in the FUS...
Items per page:
1 - 10 of 24